Categories
Health

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn is  a   biotech which has proved helpful diligently but unsuccessfully to create a single therapy, variously called Pro 140, leronlimab, and Vyrologix.

In development of this treatment, CytoDyn has cast its net wide and far both geographically and in terminology of prospective indications.

CytoDyn’s inventories of leronlimab are actually building up, whether they’ll actually be used is actually an open question.

While CYDY  has been dawdling, promote opportunities for leronlimab as being a combination treatment in the treatment of multi-drug-resistant HIV are actually closing.

I am writing my fifteenth CytoDyn (OTCQB:CYDY) article on FintechZoom to celebrate the sale made of my last few shares. The first CytoDyn post of mine, “CytoDyn: What to be able to Do When It is Too Good In order to Be True?”, set away what follows prediction:

Instead I expect it to be a serial disappointer. CEO Pourhassan offered such an extremely promotional picture in the Uptick Newswire employment interview that I came away with a poor opinion of the business.

Irony of irony, the poor viewpoint of mine of the business has grown steadily, though the disappointment hasn’t been financial. Two decades ago CytoDyn was trading <$1.00. On 2/19/20 as I create, it trades at $5.26; the closing transaction of mine was on 2/11/21 > $6.00.

What manner of stock  is it that gives a > six bagger at the moment still disappoints? Therein sits the story; permit me to explain.

CytoDyn acquired its much storied therapy (which I shall mean as leronlimab) returned in 2012, announced as follows:

CytoDyn Inc…. has completed the acquisition of Pro 140, an experimental humanized monoclonal antibody (MAB) looking for the CCR5 receptor for the therapy as well as prevention of HIV, coming from Progenics Pharmaceuticals, Inc. of Tarrytown, NY. Pro 140 is actually a late Stage II clinical development mAb with demonstrated anti viral activity in HIV infected subjects. Today’s payment of $3.5 zillion transfers ownership of the technology and linked intellectual property coming from Progenics to CytoDyn, and roughly twenty five million mg of bulk drug substance…. milestone payments upon commencement of a phase III clinical trial ($1.5 million) and the first brand new drug program endorsement ($5 million), and also royalty payments of 5 percent of net sales upon commercialization.

Since that time, CytoDyn’s leading nous, Nader Pourhassan [NP] has transformed this inauspicious acquisition right into a springboard for CytoDyn to get a market cap > $3.5 billion. It has done so in premium reliance on leronlimab.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News
CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Rather than having a pipeline with multiple therapies and many indications, it has this individual treatments as well as a “broad pipeline of indications” since it puts it. I call such pipelines, “pipedots.” In CytoDyn’s case it touts its leronlimab as a potentially advantageous therapy in dozens of indications.

Its opening banner on the website of its (below) shows an active business with diverse interests albeit focused on leronlimab, multiple disease sorts, multiple presentations in addition to multiple publications.

Could all this be smoke cigarettes and mirrors? That is a question I’ve been asking myself from the really start of the interest of mine in this business. Judging with the multiples of thousands of several remarks on listings accessible via Seeking Alpha’s CytoDyn Summary webpage, I’m far from alone in this particular question.

CytoDyn is a classic battleground, or possibly some may say cult stock. Its adherents are fiercely shielding of its prospects, quick to label any bad opinions as scurrilous short-mongering.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Leave a Reply

Your email address will not be published. Required fields are marked *